Pathological complete response in <i>RET</i>-positive non-small cell lung cancer: a case report of pralsetinib-based "sandwich" therapy.

ABSTRACT:

Background

RET gene fusions define a distinct molecular subset of non-small cell lung cancer (NSCLC) that commonly affects younger and non-smoking individuals. Selective RET inhibitors such as pralsetinib have shown favorable outcomes in advanced or metastatic settings; however, their role in perioperative or locally advanced disease remains poorly defined. Integrating targeted therapy into a multidisciplinary "sandwich" strategy, which includes neoadjuvant, surgical, and adjuvant components, may offer improved outcomes and requires further exploration.

Case description

We report the case of a 34-year-old male patient with a 15-year smoking history, who presented with persistent right-sided chest pain. Imaging revealed a 3.4 cm × 2.4 cm × 4.4 cm mass in the rig

SUBMITTER: He Q 

PROVIDER: S-EPMC12605663 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature